Are you over 18 and want to see adult content?
More Annotations
A complete backup of https://chotto-matte.com
Are you over 18 and want to see adult content?
A complete backup of https://esda.org
Are you over 18 and want to see adult content?
A complete backup of https://inmoliva.com
Are you over 18 and want to see adult content?
A complete backup of https://fromefestival.co.uk
Are you over 18 and want to see adult content?
A complete backup of https://darkduck.com
Are you over 18 and want to see adult content?
A complete backup of https://theallineed.com
Are you over 18 and want to see adult content?
A complete backup of https://lilapar.com
Are you over 18 and want to see adult content?
A complete backup of https://fantasiescometrue.com
Are you over 18 and want to see adult content?
A complete backup of https://glaucoma.org.au
Are you over 18 and want to see adult content?
A complete backup of https://themusicmansquare.org
Are you over 18 and want to see adult content?
A complete backup of https://capecodbaseball.org
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of gothunderbirds.ca
Are you over 18 and want to see adult content?
A complete backup of brandsandfilms.com
Are you over 18 and want to see adult content?
A complete backup of animalagalliance.org
Are you over 18 and want to see adult content?
A complete backup of well-of-souls.com
Are you over 18 and want to see adult content?
A complete backup of comdisonline.com
Are you over 18 and want to see adult content?
A complete backup of liveworkdream.com
Are you over 18 and want to see adult content?
Text
Info.
SPINRAZA® (NUSINERSEN) IN ADULTS have been treated with SPINRAZA*. * Based on commercial patients, early access patients, and clinical trial participants through December 2020. ‡ Includes clinical trial patients. ‡ Clinical studies of SPINRAZA included patients from 3 days to 16 years of age at first dose, but did not include sufficient numbers of subjects aged65 and over
TREATMENT CENTERS
SPINRAZA is given through a procedure called intrathecal injection and should be administered at designated treatment centers by or under the direction of a qualified healthcare provider (HCP). QUESTIONS - SPINRAZA 3 Please see additional Important Safety Information on page 14 and accompanying full Prescribing Information. POTENTIAL BENEFITS AND RISKS Individual results may vary based on several factors, including severity of disease, initiation YOU’VE FOUND A TREATMENT CENTER. WHAT MIGHT BE NEXT? INDICATION SPINRAZA is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and adult patients. SELECTED IMPORTANT SAFETY INFORMATION HIGHLIGHTS OF PRESCRIBING INFORMATION DOSAGE FORMS … Reference ID: 4625921 pneumonia or respiratory symptoms (35% vs 22%), swallowing or feeding difficulties (51% vs 29%), and requirement for respiratory support (26% vs 15%).INSURANCE SUPPORT
After you are prescribed SPINRAZA, you will be connected to your support team, including your Lead Case Manager (LCM). Your LCM can: Investigate your insurance benefits to help you understand your current coverage. Facilitate the prior authorization process for treatment. Provide information in the event of denied insuranceclaims.
LATER-ONSET SMA (TYPES 2 & 3)| SPINRAZA® (NUSINERSEN) Who: 139 adults ages 16-65 years with later-onset SMA: 2 with Type 1, 47 with Type 2, 89 with Type 3, and 1 with Type 4. Study time: 14 months. Primary outcome: Changes in motor function at 6, 10, and 14 months, measured on HFMSE. Secondary outcomes : Changes in upper limb function at 6, 10, and 14 months, measured on RULM. NAVIGATING INSURANCE AND SUPPORT PROGRAMS FOR … A GUIDE FOR PATIENTS WITH SPINAL MUSCULAR ATROPHY AND THEIR CAREGIVERS NAVIGATING INSURANCE AND SUPPORT PROGRAMS FOR SPINRAZA® (nusinersen) INDICATION SPINRAZA® (nusinersen) is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and OFFICIAL PATIENT SITE The most common side effects of SPINRAZA include lower respiratory infection, fever, constipation, headache, vomiting, back pain, and post-lumbar puncture syndrome. These are not all of the possible side effects of SPINRAZA. See safety profile. HOW SPINRAZA® (NUSINERSEN) WORKS Learn how a SPINRAZA injection effectively treats an underlying cause of SMA for those with Types 1, 2, and 3. See Safety & PrescribingInfo.
SPINRAZA® (NUSINERSEN) IN ADULTS have been treated with SPINRAZA*. * Based on commercial patients, early access patients, and clinical trial participants through December 2020. ‡ Includes clinical trial patients. ‡ Clinical studies of SPINRAZA included patients from 3 days to 16 years of age at first dose, but did not include sufficient numbers of subjects aged65 and over
TREATMENT CENTERS
SPINRAZA is given through a procedure called intrathecal injection and should be administered at designated treatment centers by or under the direction of a qualified healthcare provider (HCP). QUESTIONS - SPINRAZA 3 Please see additional Important Safety Information on page 14 and accompanying full Prescribing Information. POTENTIAL BENEFITS AND RISKS Individual results may vary based on several factors, including severity of disease, initiation YOU’VE FOUND A TREATMENT CENTER. WHAT MIGHT BE NEXT? INDICATION SPINRAZA is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and adult patients. SELECTED IMPORTANT SAFETY INFORMATION HIGHLIGHTS OF PRESCRIBING INFORMATION DOSAGE FORMS … Reference ID: 4625921 pneumonia or respiratory symptoms (35% vs 22%), swallowing or feeding difficulties (51% vs 29%), and requirement for respiratory support (26% vs 15%).INSURANCE SUPPORT
After you are prescribed SPINRAZA, you will be connected to your support team, including your Lead Case Manager (LCM). Your LCM can: Investigate your insurance benefits to help you understand your current coverage. Facilitate the prior authorization process for treatment. Provide information in the event of denied insuranceclaims.
LATER-ONSET SMA (TYPES 2 & 3)| SPINRAZA® (NUSINERSEN) Who: 139 adults ages 16-65 years with later-onset SMA: 2 with Type 1, 47 with Type 2, 89 with Type 3, and 1 with Type 4. Study time: 14 months. Primary outcome: Changes in motor function at 6, 10, and 14 months, measured on HFMSE. Secondary outcomes : Changes in upper limb function at 6, 10, and 14 months, measured on RULM. NAVIGATING INSURANCE AND SUPPORT PROGRAMS FOR … A GUIDE FOR PATIENTS WITH SPINAL MUSCULAR ATROPHY AND THEIR CAREGIVERS NAVIGATING INSURANCE AND SUPPORT PROGRAMS FOR SPINRAZA® (nusinersen) INDICATION SPINRAZA® (nusinersen) is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and HOW SPINRAZA® (NUSINERSEN) WORKS Learn how a SPINRAZA injection effectively treats an underlying cause of SMA for those with Types 1, 2, and 3. See Safety & PrescribingInfo.
DOSING | SPINRAZA® (NUSINERSEN) The recommended dosage of SPINRAZA is. 12 mg (5 mL) per administration. SPINRAZA is an intrathecal injection, or an injection into the fluid of the spine, by a specially trained HCP. The dosing schedule begins with 4 initial loading doses; the first 3 occur in 14-day intervals and the STARTING SPINRAZA® (NUSINERSEN) On the day of your treatment, the administrative staff will complete your check-in. Then the clinical staff will prepare you for treatment, and an HCP will administer your first dose of SPINRAZA. After, the administrative staff will check you out and schedule your next appointment. Your SMA360° team will follow up with you after eachdose.
SPINRAZA® (NUSINERSEN) SAFETY & SIDE EFFECTS Find information on the SPINRAZA safety profile, including potential side effects of SPINRAZA. See clinical trials, safety & PrescribingInfo.
SUPPORT | SPINRAZA® (NUSINERSEN) SMA360° is a comprehensive support services program for people prescribed SPINRAZA. SMA360° insurance and financial assistance programs are designed to help you understand your insurance benefits for SPINRAZA so that you can start treatment as quickly as possible and continue as prescribed by your HCP. Events are great opportunitiesto
WWW.SPINRAZA.COM
Your SPINRAZA circle of support. Once you or your child is prescribed SPINRAZA, you can learn about and access SMA360° support services from Biogen. Biogen’s SMA360° support program provides certain services that address nonmedical barriers to access.*. Your SMA360° team is made up of your Family Access Manager (FAM) and Lead CaseManager
SMA 360 | SPINRAZA® (NUSINERSEN) Your SPINRAZA circle of support. Once you or your child is prescribed SPINRAZA, you can learn about and access SMA360° support services from Biogen. Biogen’s SMA360° support program provides certain services that address nonmedical barriers to access.*. Your SMA360° team is made up of your Family Access Manager (FAM) and Lead CaseManager
HIGHLIGHTS OF PRESCRIBING INFORMATION LABORATORY TESTING In a clinical study (mean treatment exposure 7 months), 17 of 51 (33%) SPINRAZA-treated patients had elevated urine protein, compared to 5 of 25 (20%) sham-control patients. OFFICIAL PATIENT SITE Moved Permanently. The document has moved here.ECONSENT FORM
By signing this Authorization, I authorize my/my child's HCP, health insurance company, and pharmacy providers ("Healthcare Entities") to disclose to Biogen, and companies working with Biogen (collectively, "Biogen"), health information relating to my/my child's medical condition, treatment, and insurance coverage for Biogen to provide me/my child with (i) support services (and related OFFICIAL PATIENT SITE The most common side effects of SPINRAZA include lower respiratory infection, fever, constipation, headache, vomiting, back pain, and post-lumbar puncture syndrome. These are not all of the possible side effects of SPINRAZA. See safety profile. HOW SPINRAZA® (NUSINERSEN) WORKS Learn how a SPINRAZA injection effectively treats an underlying cause of SMA for those with Types 1, 2, and 3. See Safety & PrescribingInfo.
TREATMENT CENTERS
SPINRAZA is given through a procedure called intrathecal injection and should be administered at designated treatment centers by or under the direction of a qualified healthcare provider (HCP). SPINRAZA® (NUSINERSEN) IN ADULTS *Based on commercial patients, early access patients, and clinical trial participants through December 2020. †Includes clinical trial patients. ‡ Clinical studies of SPINRAZA included patients from 3 days to 16 years of age at first dose, but did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger patients. QUESTIONS - SPINRAZA 3 Please see additional Important Safety Information on page 14 and accompanying full Prescribing Information. POTENTIAL BENEFITS AND RISKS Individual results may vary based on several factors, including severity of disease, initiation YOU’VE FOUND A TREATMENT CENTER. WHAT MIGHT BE NEXT? INDICATION SPINRAZA is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and adult patients. SELECTED IMPORTANT SAFETY INFORMATION SUPPORT | SPINRAZA® (NUSINERSEN) Support throughout your SPINRAZA journey. With a progressive disease like SMA, your needs are likely to change over time, and you might feel like you could use a helping hand. Your healthcare provider is your go-to partner for SMA care, but we also have a team of dedicated individuals who can help you navigate your SPINRAZA treatment journey. NAVIGATING INSURANCE AND SUPPORT PROGRAMS FOR … A GUIDE FOR PATIENTS WITH SPINAL MUSCULAR ATROPHY AND THEIR CAREGIVERS NAVIGATING INSURANCE AND SUPPORT PROGRAMS FOR SPINRAZA® (nusinersen) INDICATION SPINRAZA® (nusinersen) is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and HIGHLIGHTS OF PRESCRIBING INFORMATION DOSAGE FORMS … Reference ID: 4625921 pneumonia or respiratory symptoms (35% vs 22%), swallowing or feeding difficulties (51% vs 29%), and requirement for respiratory support (26% vs 15%). LATER-ONSET SMA (TYPES 2 & 3)| SPINRAZA® (NUSINERSEN) Who: 139 adults ages 16-65 years with later-onset SMA: 2 with Type 1, 47 with Type 2, 89 with Type 3, and 1 with Type 4. Study time: 14 months. Primary outcome: Changes in motor function at 6, 10, and 14 months, measured on HFMSE. Secondary outcomes : Changes in upper limb function at 6, 10, and 14 months, measured on RULM. OFFICIAL PATIENT SITE The most common side effects of SPINRAZA include lower respiratory infection, fever, constipation, headache, vomiting, back pain, and post-lumbar puncture syndrome. These are not all of the possible side effects of SPINRAZA. See safety profile. HOW SPINRAZA® (NUSINERSEN) WORKS Learn how a SPINRAZA injection effectively treats an underlying cause of SMA for those with Types 1, 2, and 3. See Safety & PrescribingInfo.
TREATMENT CENTERS
SPINRAZA is given through a procedure called intrathecal injection and should be administered at designated treatment centers by or under the direction of a qualified healthcare provider (HCP). SPINRAZA® (NUSINERSEN) IN ADULTS *Based on commercial patients, early access patients, and clinical trial participants through December 2020. †Includes clinical trial patients. ‡ Clinical studies of SPINRAZA included patients from 3 days to 16 years of age at first dose, but did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger patients. QUESTIONS - SPINRAZA 3 Please see additional Important Safety Information on page 14 and accompanying full Prescribing Information. POTENTIAL BENEFITS AND RISKS Individual results may vary based on several factors, including severity of disease, initiation YOU’VE FOUND A TREATMENT CENTER. WHAT MIGHT BE NEXT? INDICATION SPINRAZA is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and adult patients. SELECTED IMPORTANT SAFETY INFORMATION SUPPORT | SPINRAZA® (NUSINERSEN) Support throughout your SPINRAZA journey. With a progressive disease like SMA, your needs are likely to change over time, and you might feel like you could use a helping hand. Your healthcare provider is your go-to partner for SMA care, but we also have a team of dedicated individuals who can help you navigate your SPINRAZA treatment journey. NAVIGATING INSURANCE AND SUPPORT PROGRAMS FOR … A GUIDE FOR PATIENTS WITH SPINAL MUSCULAR ATROPHY AND THEIR CAREGIVERS NAVIGATING INSURANCE AND SUPPORT PROGRAMS FOR SPINRAZA® (nusinersen) INDICATION SPINRAZA® (nusinersen) is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and HIGHLIGHTS OF PRESCRIBING INFORMATION DOSAGE FORMS … Reference ID: 4625921 pneumonia or respiratory symptoms (35% vs 22%), swallowing or feeding difficulties (51% vs 29%), and requirement for respiratory support (26% vs 15%). LATER-ONSET SMA (TYPES 2 & 3)| SPINRAZA® (NUSINERSEN) Who: 139 adults ages 16-65 years with later-onset SMA: 2 with Type 1, 47 with Type 2, 89 with Type 3, and 1 with Type 4. Study time: 14 months. Primary outcome: Changes in motor function at 6, 10, and 14 months, measured on HFMSE. Secondary outcomes : Changes in upper limb function at 6, 10, and 14 months, measured on RULM. HOW SPINRAZA® (NUSINERSEN) WORKS Learn how a SPINRAZA injection effectively treats an underlying cause of SMA for those with Types 1, 2, and 3. See Safety & PrescribingInfo.
SPINRAZA® (NUSINERSEN) IN ADULTS *Based on commercial patients, early access patients, and clinical trial participants through December 2020. †Includes clinical trial patients. ‡ Clinical studies of SPINRAZA included patients from 3 days to 16 years of age at first dose, but did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger patients. SPINRAZA® (NUSINERSEN) SAFETY & SIDE EFFECTS Find information on the SPINRAZA safety profile, including potential side effects of SPINRAZA. See clinical trials, safety & PrescribingInfo.
SUPPORT | SPINRAZA® (NUSINERSEN) Support throughout your SPINRAZA journey. With a progressive disease like SMA, your needs are likely to change over time, and you might feel like you could use a helping hand. Your healthcare provider is your go-to partner for SMA care, but we also have a team of dedicated individuals who can help you navigate your SPINRAZA treatment journey. FAQ | SPINRAZA® (NUSINERSEN) SPINRAZA is the first approved therapy for pediatric and adult patients with SMA. The effectiveness of SPINRAZA was established in the longest clinical trial program in SMA to date, which included the pivotal ENDEAR and CHERISH clinical trials.INSURANCE SUPPORT
After you are prescribed SPINRAZA, you will be connected to your support team, including your Lead Case Manager (LCM). Your LCM can: Investigate your insurance benefits to help you understand your current coverage. Facilitate the prior authorization process for treatment. Provide information in the event of denied insuranceclaims.
SMA 360 | SPINRAZA® (NUSINERSEN) Your SPINRAZA circle of support. Once you or your child is prescribed SPINRAZA, you can learn about and access SMA360° support services from Biogen. Biogen’s SMA360° support program provides certain services that address nonmedical barriers to access.*. Your SMA360° team is made up of your Family Access Manager (FAM) and Lead CaseManager
IMPORTANT SAFETY INFORMATION IMPORTANT SAFETY INFORMATION. Increased risk of bleeding complications has been observed after administration of similar medicines. Your healthcare provider should perform blood tests before you start treatment with SPINRAZA and before each dose to monitor for signs ofthese risks.
ENGLISH - SPINRAZA
A treatment for children and adults with spinal muscular atrophy (SMA) A treatment for children and adults with spinal muscular atrophy(SMA).
HIGHLIGHTS OF PRESCRIBING INFORMATION LABORATORY TESTING In a clinical study (mean treatment exposure 7 months), 17 of 51 (33%) SPINRAZA-treated patients had elevated urine protein, compared to 5 of 25 (20%) sham-control patients. OFFICIAL PATIENT SITE The most common side effects of SPINRAZA include lower respiratory infection, fever, constipation, headache, vomiting, back pain, and post-lumbar puncture syndrome. These are not all of the possible side effects of SPINRAZA. See safety profile. SPINRAZA® (NUSINERSEN) IN ADULTS have been treated with SPINRAZA*. * Based on commercial patients, early access patients, and clinical trial participants through December 2020. ‡ Includes clinical trial patients. ‡ Clinical studies of SPINRAZA included patients from 3 days to 16 years of age at first dose, but did not include sufficient numbers of subjects aged65 and over
TREATMENT CENTERS
SPINRAZA is given through a procedure called intrathecal injection and should be administered at designated treatment centers by or under the direction of a qualified healthcare provider (HCP). QUESTIONS - SPINRAZA 3 Please see additional Important Safety Information on page 14 and accompanying full Prescribing Information. POTENTIAL BENEFITS AND RISKS Individual results may vary based on several factors, including severity of disease, initiation YOU’VE FOUND A TREATMENT CENTER. WHAT MIGHT BE NEXT? INDICATION SPINRAZA is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and adult patients. SELECTED IMPORTANT SAFETY INFORMATION SUPPORT | SPINRAZA® (NUSINERSEN) Support throughout your SPINRAZA journey. With a progressive disease like SMA, your needs are likely to change over time, and you might feel like you could use a helping hand. Your healthcare provider is your go-to partner for SMA care, but we also have a team of dedicated individuals who can help you navigate your SPINRAZA treatment journey. NAVIGATING INSURANCE AND SUPPORT PROGRAMS FOR … A GUIDE FOR PATIENTS WITH SPINAL MUSCULAR ATROPHY AND THEIR CAREGIVERS NAVIGATING INSURANCE AND SUPPORT PROGRAMS FOR SPINRAZA® (nusinersen) INDICATION SPINRAZA® (nusinersen) is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric andINSURANCE SUPPORT
After you are prescribed SPINRAZA, you will be connected to your support team, including your Lead Case Manager (LCM). Your LCM can: Investigate your insurance benefits to help you understand your current coverage. Facilitate the prior authorization process for treatment. Provide information in the event of denied insuranceclaims.
LATER-ONSET SMA (TYPES 2 & 3)| SPINRAZA® (NUSINERSEN) Who: 139 adults ages 16-65 years with later-onset SMA: 2 with Type 1, 47 with Type 2, 89 with Type 3, and 1 with Type 4. Study time: 14 months. Primary outcome: Changes in motor function at 6, 10, and 14 months, measured on HFMSE. Secondary outcomes : Changes in upper limb function at 6, 10, and 14 months, measured on RULM. HIGHLIGHTS OF PRESCRIBING INFORMATION DOSAGE FORMS … Reference ID: 4625921 pneumonia or respiratory symptoms (35% vs 22%), swallowing or feeding difficulties (51% vs 29%), and requirement for respiratory support (26% vs 15%). OFFICIAL PATIENT SITE The most common side effects of SPINRAZA include lower respiratory infection, fever, constipation, headache, vomiting, back pain, and post-lumbar puncture syndrome. These are not all of the possible side effects of SPINRAZA. See safety profile. SPINRAZA® (NUSINERSEN) IN ADULTS have been treated with SPINRAZA*. * Based on commercial patients, early access patients, and clinical trial participants through December 2020. ‡ Includes clinical trial patients. ‡ Clinical studies of SPINRAZA included patients from 3 days to 16 years of age at first dose, but did not include sufficient numbers of subjects aged65 and over
TREATMENT CENTERS
SPINRAZA is given through a procedure called intrathecal injection and should be administered at designated treatment centers by or under the direction of a qualified healthcare provider (HCP). QUESTIONS - SPINRAZA 3 Please see additional Important Safety Information on page 14 and accompanying full Prescribing Information. POTENTIAL BENEFITS AND RISKS Individual results may vary based on several factors, including severity of disease, initiation YOU’VE FOUND A TREATMENT CENTER. WHAT MIGHT BE NEXT? INDICATION SPINRAZA is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and adult patients. SELECTED IMPORTANT SAFETY INFORMATION SUPPORT | SPINRAZA® (NUSINERSEN) Support throughout your SPINRAZA journey. With a progressive disease like SMA, your needs are likely to change over time, and you might feel like you could use a helping hand. Your healthcare provider is your go-to partner for SMA care, but we also have a team of dedicated individuals who can help you navigate your SPINRAZA treatment journey. NAVIGATING INSURANCE AND SUPPORT PROGRAMS FOR … A GUIDE FOR PATIENTS WITH SPINAL MUSCULAR ATROPHY AND THEIR CAREGIVERS NAVIGATING INSURANCE AND SUPPORT PROGRAMS FOR SPINRAZA® (nusinersen) INDICATION SPINRAZA® (nusinersen) is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric andINSURANCE SUPPORT
After you are prescribed SPINRAZA, you will be connected to your support team, including your Lead Case Manager (LCM). Your LCM can: Investigate your insurance benefits to help you understand your current coverage. Facilitate the prior authorization process for treatment. Provide information in the event of denied insuranceclaims.
LATER-ONSET SMA (TYPES 2 & 3)| SPINRAZA® (NUSINERSEN) Who: 139 adults ages 16-65 years with later-onset SMA: 2 with Type 1, 47 with Type 2, 89 with Type 3, and 1 with Type 4. Study time: 14 months. Primary outcome: Changes in motor function at 6, 10, and 14 months, measured on HFMSE. Secondary outcomes : Changes in upper limb function at 6, 10, and 14 months, measured on RULM. HIGHLIGHTS OF PRESCRIBING INFORMATION DOSAGE FORMS … Reference ID: 4625921 pneumonia or respiratory symptoms (35% vs 22%), swallowing or feeding difficulties (51% vs 29%), and requirement for respiratory support (26% vs 15%). HOW SPINRAZA® (NUSINERSEN) WORKS Learn how a SPINRAZA injection effectively treats an underlying cause of SMA for those with Types 1, 2, and 3. See Safety & PrescribingInfo.
DOSING | SPINRAZA® (NUSINERSEN) The recommended dosage of SPINRAZA is. 12 mg (5 mL) per administration. SPINRAZA is an intrathecal injection, or an injection into the fluid of the spine, by a specially trained HCP. The dosing schedule begins with 4 initial loading doses; the first 3 occur in 14-day intervals and the STARTING SPINRAZA® (NUSINERSEN) On the day of your treatment, the administrative staff will complete your check-in. Then the clinical staff will prepare you for treatment, and an HCP will administer your first dose of SPINRAZA. After, the administrative staff will check you out and schedule your next appointment. Your SMA360° team will follow up with you after eachdose.
SPINRAZA® (NUSINERSEN) SAFETY & SIDE EFFECTS Find information on the SPINRAZA safety profile, including potential side effects of SPINRAZA. See clinical trials, safety & PrescribingInfo.
SUPPORT | SPINRAZA® (NUSINERSEN) Support throughout your SPINRAZA journey. With a progressive disease like SMA, your needs are likely to change over time, and you might feel like you could use a helping hand. Your healthcare provider is your go-to partner for SMA care, but we also have a team of dedicated individuals who can help you navigate your SPINRAZA treatment journey.WWW.SPINRAZA.COM
Your SPINRAZA circle of support. Once you or your child is prescribed SPINRAZA, you can learn about and access SMA360° support services from Biogen. Biogen’s SMA360° support program provides certain services that address nonmedical barriers to access.*. Your SMA360° team is made up of your Family Access Manager (FAM) and Lead CaseManager
SMA 360 | SPINRAZA® (NUSINERSEN) Your SPINRAZA circle of support. Once you or your child is prescribed SPINRAZA, you can learn about and access SMA360° support services from Biogen. Biogen’s SMA360° support program provides certain services that address nonmedical barriers to access.*. Your SMA360° team is made up of your Family Access Manager (FAM) and Lead CaseManager
IMPORTANT SAFETY INFORMATION IMPORTANT SAFETY INFORMATION. Increased risk of bleeding complications has been observed after administration of similar medicines. Your healthcare provider should perform blood tests before you start treatment with SPINRAZA and before each dose to monitor for signs ofthese risks.
HIGHLIGHTS OF PRESCRIBING INFORMATION LABORATORY TESTING In a clinical study (mean treatment exposure 7 months), 17 of 51 (33%) SPINRAZA-treated patients had elevated urine protein, compared to 5 of 25 (20%) sham-control patients.ECONSENT FORM
By signing this Authorization, I authorize my/my child's HCP, health insurance company, and pharmacy providers ("Healthcare Entities") to disclose to Biogen, and companies working with Biogen (collectively, "Biogen"), health information relating to my/my child's medical condition, treatment, and insurance coverage for Biogen to provide me/my child with (i) support services (and related * Visit Healthcare Professional Site * Safety Information * Prescribing Information * Prescribing Information en español * Find a Treatment Center * Sign Up for Updates*
* Visit HCP Site
* Safety Info
* Prescribing Info
Toggle navigation
A treatment for children and adults with spinal muscular atrophy(SMA) .
*
*
* Why SPINRAZA
* How SPINRAZA Works * Later-Onset Studies* Early-Onset Study
* Presymptomatic Study* Safety Profile
* TAKING SPINRAZA
* Getting Started
* Dosing
* Find a Treatment Center* SPINRAZA STORIES
* Adults on SPINRAZA * Children on SPINRAZA* What is SMA
* About SMA
* SUPPORT
* Support & Resources* Insurance Support
* SMA360°™
* Events
* FAQs
*
*
A treatment for children and adults with spinal muscular atrophy (SMA) A treatment for children and adults with spinal muscularatrophy (SMA) .
*
* Visit Healthcare Professional Site * Safety Information * Prescribing Information * Prescribing Information en español * Find a Treatment Center * Sign Up for Updates TALK WITH YOUR DOCTOR TO GET STARTED Individual results may vary based on several factors, including severity of disease, initiation of treatment, and duration of therapy. TALK WITH YOUR DOCTOR TO GET STARTED FOR THE 11,000+ PEOPLE WHO HAVE BEEN TREATED WITH SPINRAZA WORLDWIDE,* VICTORIES ARE PERSONAL. *Based on commercial patients, early access patients, and clinical trial participants through December 2020.CLICK HERE FOR
INFORMATION ABOUT
CORONAVIRUS (COVID-19) DISCOVER SPINRAZA: THE FIRST FDA-APPROVEDTREATMENT FOR SMA
7+ years
Safety and efficacy
evaluated
in the longest
clinical trial in
SMA to date
3x/year
SPINRAZA is DIRECTLY DELIVEREDto
the central nervous system (CNS)where
motor neuron loss begins.After 4
initial loading doses,SPINRAZA is
given 3 times a year. FROM 3 DAYS†TO 80 YEARS OLD‡§ There’s someone from almost every age group who has been treatedwith SPINRAZA.
WATCH SOME OF THEIR STORIES †Includes clinical trial patients. ‡Clinical studies of SPINRAZA included patients from 3 days to 16 years of age at first dose, but did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger patients. §Based on commercial patients in the US (including Puerto Rico) through December 2020. DEMONSTRATED EFFICACY IN PEOPLE WITH EARLY- AND LATER-ONSET SMASEE THE DATA
SAFETY & SIDE EFFECTS The most common side effects of SPINRAZA include lower respiratory infection, fever, constipation, headache, vomiting, back pain, and post-lumbar puncture syndrome. These are not all of the possible side effects of SPINRAZA.SEE SAFETY PROFILE
HOW SPINRAZA WORKS
SPINRAZA targets an underlying cause of muscle weakness in SMA.SEE HOW IT WORKS
IMPORTANT SAFETY INFORMATION INCREASED RISK OF BLEEDING COMPLICATIONS has been observed after administration of similar medicines. Your healthcare provider should perform blood tests before you start treatment with SPINRAZA and before each dose to monitor for signs of these risks. Seek medical attention if unexpected bleeding occurs. INCREASED RISK OF KIDNEY DAMAGE, INCLUDING POTENTIALLY FATAL ACUTE INFLAMMATION OF THE KIDNEY, has been observed after administration of similar medicines. Your healthcare provider should perform urine testing before you start treatment with SPINRAZA and before each dose to monitor for signs of this risk. THE MOST COMMON SIDE EFFECTS OF SPINRAZA INCLUDE lower respiratory infection, fever, constipation, headache, vomiting, back pain, and post-lumbar puncture syndrome. These are not all of the possible side effects of SPINRAZA. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. BEFORE TAKING SPINRAZA, tell your healthcare provider if you are pregnant or plan to become pregnant. PLEASE SEE FULL PRESCRIBING INFORMATION.
This information is not intended to replace discussions with your healthcare provider.INDICATION
SPINRAZA® (nusinersen) is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and adult patients. IMPORTANT SAFETY INFORMATION& INDICATION
IMPORTANT SAFETY INFORMATION& INDICATION
IMPORTANT SAFETY INFORMATION INCREASED RISK OF BLEEDING COMPLICATIONS has been observed after administration of similar medicines. Your healthcare provider should perform blood tests before you start treatment with SPINRAZA and before each dose to monitor for signs of these risks. Seek medical attention if unexpected bleeding occurs.INDICATION
SPINRAZA® (nusinersen) is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and adult patients. IMPORTANT SAFETY INFORMATION& INDICATION
IMPORTANT SAFETY INFORMATION INCREASED RISK OF BLEEDING COMPLICATIONS has been observed after administration of similar medicines. Your healthcare provider should perform blood tests before you start treatment with SPINRAZA and before each dose to monitor for signs of these risks. Seek medical attention if unexpected bleeding occurs. INCREASED RISK OF KIDNEY DAMAGE, INCLUDING POTENTIALLY FATAL ACUTE INFLAMMATION OF THE KIDNEY, has been observed after administration of similar medicines. Your healthcare provider should perform urine testing before you start treatment with SPINRAZA and before each dose to monitor for signs of this risk. THE MOST COMMON SIDE EFFECTS OF SPINRAZA INCLUDE lower respiratory infection, fever, constipation, headache, vomiting, back pain, and post-lumbar puncture syndrome. These are not all of the possible side effects of SPINRAZA. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. BEFORE TAKING SPINRAZA, tell your healthcare provider if you are pregnant or plan to become pregnant. PLEASE SEE FULL PRESCRIBING INFORMATION.
This information is not intended to replace discussions with your healthcare provider.INDICATION
SPINRAZA® (nusinersen) is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and adult patients.STAY CONNECTED
Sign up with us to receive the latest news, support information, andupcoming events.
Please enter a valid email address.Why SPINRAZA
How SPINRAZA Works
Later-Onset Studies
Early-Onset Study
Presymptomatic StudySafety Profile
TAKING SPINRAZA
Getting Started
Dosing Find a TreatmentCenter
SPINRAZA STORIES
Adults on SPINRAZA
Children on SPINRAZAWHAT IS SMA
About SMA
Support
Support and ResourcesInsurance Support
SMA360°™
Events
FAQs
* Privacy Policy
* Terms and Conditions* Contact Us
* Privacy Policy
* Terms and Conditions* Contact Us
©2021 Biogen. All rights reserved. This site is intended for US residents aged 18 and older.SPZ-US-3384 v3
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0